MedTrace Logo

Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)

NCT00510965 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-06-15

No results posted yet for this study

Summary

The purpose of the study is to investigate the efficacy of a new drug called ranibizumab in the treatment of choroidal neovascularization in underlying angioid streaks due to Pseudoxanthoma elasticum. 10 patients will receive monthly injections of the drug in one eye over a period of one year.

Conditions

  • Choroidal Neovascularization

Interventions

DRUG

Intravitreal injection ranibizumab

Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University Hospital, Bonn

    lead OTHER

Principal Investigators

  • Frank G. Holz, MD · University of Bonn, Department of Ophthalmology

  • Hendrik PN Scholl, MD, MA · University of Bonn

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00510965 on ClinicalTrials.gov